NeuroSense and Genetika+ to collaborate in drug development for Alzheimer’s

NeuroSense Therapeutics announced a collaboration in Alzheimer’s Disease drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense’s currently ongoing Phase 2 AD clinical trial, leverages Genetika+’s technology that derives frontal cortex neurons from individual patients’ blood to quantify drug-induced neuronal plasticity in vitro. The Genetika+ technology serves as a human AD disease model and will be used to correlate clinical response with cellular effects, for mechanistic drug insights and patient subset identification, supporting drug development and potentially commercialization. NeuroSense’s Phase 2 randomized, prospective double-blind, placebo-controlled study is designed to evaluate the therapeutic potential of PrimeC in treating AD. The study is expected to reveal the safety of PrimeC in AD, as well as shed light on the efficacy and biological activity of this combination therapy in this indication.